Originally formed in 1992 and based in Edinburgh, Archangels is a prominent business angel syndicate which has been at the forefront of early stage investing in Scotland for more than a quarter of a century.

Latest News

Sorting:
  • PhysioMedics Steps in to Tackle Covid19 Lockdown Neck and Back Pain Emergency

    Millions of workers operating from home could be creating a backlog of neck and back pain complaints which the NHS will struggle to cope with. Now physiotherapy experts at PhysioWizard®, the UK’s first clinically validated digital triage service for muscle and joint problems, are so concerned that they have stepped in to offer their online […]

  • Arrayjet Signs Seven Figure US Contract

    Arrayjet has signed a seven-figure deal with CDI Laboratories to further the US firm’s research and development programme. The contract is said to be worth in the region of $1 million (£797,000) and is the second installation of Arrayjet equipment at CDI. The new IRIS Optical system joins the Arrayjet Ultra Marathon II microarray printer […]

  • Archangels Leads Further Investment in Scottish Innovators During Lockdown

    Archangels has led investment of £3.3 million in innovative Scottish companies during the Coronavirus lockdown. Archangels’ Q2 (1st April – 30th June) deals data released today (7th July, 2020) reveals that three of our portfolio companies – Calcivis, BDD and Reactec – have received follow-on funding during the period, with £1.9m of the committed investment […]

  • Reactec Funding Round Supports Development of Social Distancing Tech

    Edinburgh-based Reactec has completed a further £700,000 round of fundraising for the ongoing development of its innovative personal monitoring equipment and reporting technology. This will include its recently launched innovative SAFE-DISTANCE device to enable social distancing among workers. The funding round was led by Archangels, with co-funding from Scottish Investment Bank, the investment arm of […]

  • MGB Biopharma Announces Successful Outcome from Phase II Clinical Study

    Study confirms MGB-BP-3 offers the potential for a new gold standard in treating Clostridium difficile Infection MGB Biopharma, the Glasgow-based biopharmaceutical company developing a novel class of anti-infectives, today announces the successful conclusion of its Phase II clinical study into MGB-BP-3, for the treatment of Clostridium difficile Infection (CDI). The study confirms that the drug […]

  • Reactec’s Technology Repurposed for Social Distancing

    Social distancing solution launched to protect employees returning to work Edinburgh-based Reactec, has repurposed its proven system for monitoring workers’ exposure to health risk to create “Safedistance”, which enables employers to manage the social distancing of their workforce within construction, rail, manufacturing and other workplaces. Safedistance is based on an industrial grade wrist-worn device and […]

Company portfolio

  • Archangel Investors Ltd
  • Archangel Investors Ltd
  • Archangel Investors Ltd
  • RT @GetAdministrate: Here's why IT teams love @GetAdministrate: our open #API, developer portal, native integrations, & a dedicated Pro Ser…
    Archangel Investors Ltd about 7 days ago
  • RT @fiosgenomics: Calling all junior project managers, business development associates and bioinformaticians. Fios is expanding! We are loo…
    Archangel Investors Ltd about 11 days ago
  • RT @Blackford: Listen to Richard Ljuhar, CEO of @ImageBiopsyLab, as he talks about the benefits of partnering with Blackford 🤝 #partnership
    Archangel Investors Ltd about 11 days ago

See our ‘Impact evaluation of activities report’ by the Hunter Centre for Entrepreneurship at The University of Strathclyde.